Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

Whole blood, as one of the most significant biological fluids, provides critical information for
health management and disease monitoring. Over the past 10 years, advances in …

Abnormal assembly of tau, α-synuclein, TDP-43 and amyloid-β proteins into amyloid
filaments defines most human neurodegenerative diseases. Genetics provides a direct link …

Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

To elucidate the role of Tau isoforms and post-translational modification (PTM) stoichiometry
in Alzheimer's disease (AD), we generated a high-resolution quantitative proteomics map of …

Alzheimer's disease is a rather complex neurodegenerative disease, which is attributed to a
combination of multiple factors. Among the many pathological pathways, synaptic …

Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, develo** effective therapies to …